Sunday, November 03, 2013 11:40:50 AM
If anyone is familiar with other sites dedicated to treating patients then please feel free to post this. If you take Vascepa you should post your experience. We need to educate potential patients and enroll their support with the FDA. You can see my post in the Heart disease community.
What I posted
I actually use this drug at 2g and previously tried Plusepa and Krill oil to lower my triglycerides and ease the muscle pain I have by taking atorvastatin. I also tried OTC Niacin at 750mg and COQ-10 and all I was able to gain was a case of reflux. I stopped taking all the supplements and the reflux went away but not the dull ache from the statin. Then I heard about this new prescription drug Vascepa. After educating my cardiologist he gave me a prescription and I started this drug in June. Within 3 weeks I was virtually ache free and could lift weights and I am now working out 3 days and sometimes 5 days per week. Pain free and my entire cholesterol profile is down on average 9% since my last test and even down compared to a year's worth of tests. My Cardiologist let me know that if my test results remain the same on my next visit he will lower my statin dose to the lowest level. It has taken over 2 years to get there and adding Vascepa did the trick.
Vascepa is a highly purified and prescription grade drug made from fish oil. It is unlike Lovaza and contains no DHA or other acids. Vascepa (icosapent ethyl) capsules are the first FDA approved EPA only Omega-3 fatty acid. Vascepa is a prescription medicine, used along with a low-fat and low-cholesterol diet, to lower high triglycerides (fats). You can read more about Vascepa by visiting their website: http://www.vascepa.com/ you can see a comparison of Vascepa against Lovaza by visiting this site: www.buyvascepa.com. Unlike Lovaza and other fish oil supplements Vascepa does not increase LDL Cholesterol or carry Afib warnings. Vascepa side effects are comparable to a placebo.
I could also use the help of this community to please sign the petition that is linked below.
Recently, the FDA indicated it would not approve Vascepa for those on statin therapy with cholesterol levels from 200-500. The FDA rationale seems to be contrary to what our doctors are telling us that "lowering triglycerides does not produce fewer cardiovascular events". The FDA wants proof that lowering trigs reduces CVE events and requires results from an outcome study that is underway. The results of this study are expected in the next 4 years. In the meantime, the actions by the FDA limit drugs available to treat those like myself who suffer with atherosclerosis. These limits are in the form of prescription coverage our insurance company will allow. Right now I have Tier III coverage but these actions might cause my insurance company to drop coverage for my condition. Further, with all of the new regulations doctors do not have time to educate themselves on the latest treatments and drug companies actually perform a service when they can market to an indication. Don't let the FDA take away your ability to add a safe and effective drug to your treatment. The details about the drug and the misguided action of the FDA are contained in the petition.
http://www.thepetitionsite.com/176/817/515/urge-the-fda-to-approve-vascepa-for-mixed-dyslipidemia/
Recent AMRN News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 08:42:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/30/2024 08:10:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2024 08:10:08 PM
- Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 10/30/2024 08:05:00 PM
- Amarin Announces Two Upcoming Investor Events • GlobeNewswire Inc. • 10/01/2024 12:00:00 PM
- Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe • GlobeNewswire Inc. • 09/09/2024 11:30:00 AM
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress • GlobeNewswire Inc. • 08/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 09:30:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:05:34 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 11:05:26 AM
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 09:30:08 PM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
FEATURED North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • Nov 4, 2024 9:00 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM